Conference Call with Dr. Lal Pathlabs Management and Analysts on Q1FY23 Performance and Outlook. Listen to the full earnings transcript.
Healthcare Services firm Dr. Lal Pathlabs Announced Q1FY23 Result : Non-Covid revenue up by 25% Covid revenue declined by 91% Normalised EBITDA at Rs 126 Cr with margin at 25% PBT at Rs 81 Cr with margin at 16%, and PAT Rs 58 Cr with margin at 12% Operating Revenue decreased by 17% in Q1 FY23 to Rs. 503 Cr vs Rs 607 Cr in Q1 FY22 Non-Covid Revenue increased by 25% in Q1 FY23 to Rs. 482 Cr vs Rs 386 Cr in Q1 FY22 Covid and Allied contributed 4% to Revenue in Q1 FY23, 36% in Q1 FY22 Normalised EBITDA (after adjustment for stock based compensation, CSR) for Q1 FY21 is at Rs. 126 Cr (margins 25%) Vs Rs 199 Cr in the same quarter last year Normalised PBT at Rs 94 Cr, margins 18.6% vs Rs 179 Cr. in Q1 last year Normalised PAT at Rs 71 Cr, margins 14.0% vs Rs 134 Cr. in Q1 last year Interim Dividend of Rs. 6 per equity share of Rs. 10 each has been approved by the Board Result PDF